| Ytd | -99.45% | |
| 1y | -99.73% |
| Open | 2.76 | Prev Close | 2.75 | Low | 2.65 | High | 3.16 | Mkt Cap | 1.18M |
| Vol | 234.00K | Avg Vol | 24.90K | EPS | 1473.00 | P/E | 0.00 | Forward P/E | -0.37 |
| Beta | 0.88 | Short Ratio | 1.12 | Inst. Own | 1.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 14.52 | 200-d Avg | 208.47 | 1yr Est | 6.00 |
JAGX News
Reverse split approved at April 2026 Special Meeting of StockholdersShares of Jaguar Health common s
Reverse split approved at April 2026 Special Meeting of Stockholders Shares of Jaguar Health common
Shares of Jaguar Health Inc. (NASDAQ:JAGX) are trading lower Thursday morning as investors evaluate
Jaguar Health is trading lower Thursday as investors weigh the clinical timeline for its rare pediat
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announce
Continuation of treatment with blinded doses of crofelemer in the extension phase of the trial will
Gainers Indaptus Therapeutics (NASDAQ:INDP) stock increased by 46.7% to $1.79 during Tuesday's
Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market s
Gainers iSpecimen (NASDAQ:ISPC) shares increased by 10.4% to $1.7 during Friday's after-market
Gainers Immuron (NASDAQ:IMRN) shares moved upwards by 48.2% to $1.65 during Friday's regular se
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adju
Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced the initiation of the commercia
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide
Jaguar Health, Inc. (JAGX) Q2 2026 Earnings Call Prepared Remarks Transcript
Jaguar Health (NASDAQ:JAGX) released second-quarter financial results and hosted an earnings call on
Company remains sharply focused on its ongoing global development program for crofelemer for rare in
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(15.70) per share. This is a 95.63 percent
Company plans to file its Earnings Report on August 19, 2026 on Form 10-Q for the quarter ended June
Jaguar Animal Health, Inc. (NASDAQ: JAGX - Get Free Report)'s share price crossed below its 200-day
As announced, Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 upo
As announced , Jaguar received an upfront payment of $16M of non-dilutive capital in January 2026 up
Gainers Autonomix Medical (NASDAQ:AMIX) stock rose 49.1% to $4.1 during Tuesday's after-market
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to prov
Neonorm® Dog extends Jaguar's existing Neonorm product franchise beyond foals and calves to provide
Gainers NovoCure (NASDAQ:NVCR) shares moved upwards by 27.7% to $19.88 during Thursday's regula
As announced, Napo has previously provided crofelemer powder for oral solution to treat select infan
Jaguar remains sharply focused on its ongoing global development program for oral crofelemer as adju
Gainers Anixa Biosciences (NASDAQ:ANIX) shares rose 10.0% to $3.65 during Friday's pre-market s
Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.6% to $0.18 during Thursday's
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF
Major M&A deals this week include: Adobe buys Topaz Labs, Rise Baking Company purchases Jimmy
Company remains sharply focused on its ongoing global development program for crofelemer for rare in
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the company has completed
Jaguar's recently completed pivotal effectiveness study of crofelemer for the treatment of CID in do
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that i
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Scienc
Reminder: Lisa Conte, Jaguar's founder & CEO, to present on June 24, 2026 at the Life Sciences Virtu
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that the results of a preclinic
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post GLP-1 weight loss ma
Whole leaf coca extract under evaluation is Magdalena's drug candidate for post-GLP-1 weight loss ma
Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, presid
Click here to register for event To access the replay of the June 10, 2026 presentation by Lisa Cont
Lisa Conte, Jaguar's founder, president & CEO, presenting virtually on June 10, 2026 at the Emerging
Jaguar Health (NASDAQ:JAGX) reported quarterly losses of $(13.60) per share which missed the analyst
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) announced tha
Jaguar Health Inc. shares are climbing Wednesday after preliminary FDA talks on Breakthrough Therapy
Preliminary discussion with the Division of Gastroenterology at U.S. Food and Drug Administration (F
Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar) today announced topline results from the completion of it